p 9 r k 8 9 a t x u 8 l s i x 6 q o u c 2 w c b zp 9 r k 8 9 a t x u 8 l s i x 6 q o u c 2 w c b z

【lennox thermostat cannot communicate with smart hub】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks

Although

Hologic,lennox thermostat cannot communicate with smart hub Inc.

【lennox thermostat cannot communicate with smart hub】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks


(NASDAQ:

【lennox thermostat cannot communicate with smart hub】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks


HOLX

【lennox thermostat cannot communicate with smart hub】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks


) acquired


Cynosure


to achieve a higher weighted average market growth rate, Cynosure's main businesses have not delivered as expected, according to Morgan Stanley.


The Analyst


Morgan Stanley’s David Lewis downgraded


Hologic


from


Equal-weight to Underweight


and cut the price target from $44 to $39.


The Thesis


Hologic diversified into aesthetics with its purchase of Cynosure, with expectations of generating higher WAMGR, Lewis said in the Wednesday downgrade note.


Yet MonaLisa Touch and SculpSure — which drove almost all of Cynosure’s growth prior to the acquisition — have not returned to their pre-acquisition levels, the analyst said.


The body sculpting channel is showing signs of saturation, and the company's women’s health strategy appears flawed given the FDA’s latest scrutiny of vaginal rejuvenation, Lewis said.


Competition for NovaSure will intensify if Channel Medsystem’s Cerene snags FDA approval in mid-2019, he said.


Hologic operates in slower growth end markets versus its peers and has a WAMGR of around 3.5 percent, which is significantly below that the competition's 5 percent, the analyst said.


“A structural 3-percent organic and 8-percent EPS growth profile is below peers at 5-6 percent organic and double-digit earnings growth, which suggests Hologic is likely to relatively underperform peers."


Price Action


Hologic shares were trading down 6.45 percent at $38.45 at the time of publication Wednesday.


Related Links:


Hologic Downgraded By BofA As Cynosure Headwinds Persist


Hologic: Meet Goldman Sach's New 'Conviction Buy'


Photo courtesy of Hologic.


Latest Ratings for HOLX


Jan 2019


Morgan Stanley


Downgrades


Equal-Weight


Underweight


Nov 2018


RBC Capital


Maintains


Sector Perform


Sector Perform


Oct 2018


Morgan Stanley


Maintains


Equal-Weight


Equal-Weight


View More Analyst Ratings for HOLX


View the Latest Analyst Ratings


See more from Benzinga


JPMorgan Sees Buying Opportunity In Torchmark


Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend


Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation


© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


View comments


赞(6)
未经允许不得转载:>p 9 r k 8 9 a t x u 8 l s i x 6 q o u c 2 w c b z » 【lennox thermostat cannot communicate with smart hub】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks